Ospemifene
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ospemifene?
Summarize this article for a 10 year old
Ospemifene (brand names Osphena and Senshio produced by Shionogi) is an oral medication indicated for the treatment of dyspareunia – pain during sexual intercourse – encountered by some women, more often in those who are post-menopausal. Ospemifene is a selective estrogen receptor modulator (SERM)[4] acting similarly to an estrogen on the vaginal epithelium, building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy."[5]
Clinical data | |
---|---|
Trade names | Osphena, Senshio |
Other names | Deaminohydroxytoremifene |
License data |
|
Routes of administration | By mouth |
Drug class | Selective estrogen receptor modulator |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
ECHA InfoCard | 100.190.672 |
Chemical and physical data | |
Formula | C24H23ClO2 |
Molar mass | 378.90 g·mol−1 |
3D model (JSmol) | |
| |
|
The medication was approved by the FDA in February 2013[6] and by the European Commission for marketing in the EU in January 2015.[7]